SCARs Label Warning For OTC PPIs In US Starts With Perrigo’s 131 Omeprazole Product Options
FDA approves warning for severe cutaneous adverse reactions on labeling for Perrigo's 131 20-mg omeprazole delayed-release tablet products across unflavored and cool mint or wild berry-mint options and 14-, 28- and 42-count packages.
You may also be interested in...
Rather than reflecting what’s coming in the way of spinoffs, leadership, product approvals or deal closings, firms’ July-September results will reveal influences from inflation and supply chain problems. Like manufacturers across industries, US consumer health product firms are dealing with US currency strengthening and potentially driving down revenues through losses in foreign exchange.
FDA approves request after Nexium 24HR marketer Haleon responded March to changes-being-effected letter asking for label change to the delayed-release PPI.
A better than expected first-half performance has put Haleon on a sure footing for the rest of the year following its recent demerger from GSK.